At the 2025 SNMMI Annual Meeting, GE HealthCare unveiled a robust lineup of theranostics-enabling innovations that are reshaping the future of precision oncology. Central to this is the debut of LesionID Pro with automated zero-click pre-processing, an AI-powered tool from GE’s MIM Software. This advancement automates one of the most labor-intensive aspects of cancer imaging—whole-body tumor burden analysis—by eliminating the need for manual lesion segmentation and physiologic uptake removal. By delivering reliable tumor volume statistics in real time, this tool significantly enhances physician workflow and decision-making accuracy.
The broader theranostics ecosystem showcased by GE HealthCare emphasizes comprehensive support across the care continuum. Technologies like Omni Legend PET/CT, StarGuide SPECT/CT, and Aurora dual-head SPECT/CT offer exceptional imaging capabilities for disease detection and therapy monitoring, with features such as reduced scan time, dose minimization, and improved lesion visualization. Additionally, the MINItrace Magni cyclotron supports decentralized, in-house production of PET tracers and radiometals—making theranostics more accessible at the local level. These technologies are seamlessly integrated with software platforms like the Theranostics Pathway Manager Tile, which simplifies clinical coordination and patient tracking throughout the treatment journey.
By combining advanced imaging, radiopharmaceutical production, AI-powered analytics, and care coordination tools, GE HealthCare is uniquely positioned to drive the global adoption of theranostics. This patient-centered approach allows clinicians to personalize treatments based on precise molecular and functional data—helping to improve diagnostic accuracy, treatment outcomes, and operational efficiency. GE’s commitment to innovation across every step of the theranostics pathway reinforces its leadership in advancing precision care and transforming the future of oncology treatment.
MedTech Spectrum's Summary
End-to-End Theranostics Innovation: GE HealthCare’s integrated solutions—including AI-powered LesionID Pro, advanced PET/SPECT imaging systems, and in-house radiopharmaceutical production—streamline the entire theranostics pathway, enhancing precision and accessibility.
Enhanced Clinical Decision-Making: Tools like zero-click tumor burden analysis and real-time care coordination software enable faster, more accurate diagnostic and therapeutic decisions, supporting personalized cancer care.
Driving the Future of Precision Oncology: By uniting imaging, informatics, and therapy tools, GE HealthCare is transforming how clinicians detect, treat, and monitor cancer—empowering better outcomes and operational efficiency worldwide.
